Patents by Inventor Kazunori Kurihara

Kazunori Kurihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10385052
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: August 20, 2019
    Assignee: Nissan Chemical Corporation
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Publication number: 20180099966
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is 0 or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Patent number: 9890165
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: February 13, 2018
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Publication number: 20170044161
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like: each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: May 11, 2015
    Publication date: February 16, 2017
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo WATANABE, Keiji TAKAHASHI, Keishi HAYASHI, Takanori NAKAMURA, Masataka MINAMI, Kazunori KURIHARA, Akio YAMAMOTO, Takuya NISHIMURA, Miyuki UNI, Toshihiko KAMIYAMA, Shunsuke IWAMOTO
  • Patent number: 9475813
    Abstract: To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: October 25, 2016
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Keiji Takahashi, Tsuneo Watanabe, Keishi Hayashi, Kazunori Kurihara, Takanori Nakamura, Akio Yamamoto, Takuya Nishimura, Toshihiko Kamiyama, Yuuki Hidaka
  • Publication number: 20150368245
    Abstract: To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 24, 2015
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Keiji TAKAHASHI, Tsuneo WATANABE, Keishi HAYASHI, Kazunori KURIHARA, Takanori NAKAMURA, Akio YAMAMOTO, Takuya NISHIMURA, Toshihiko KAMIYAMA, Yuuki HIDAKA
  • Patent number: 8101774
    Abstract: The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: January 24, 2012
    Assignee: Japan Tobacco Inc.
    Inventors: Atsushi Hagiwara, Taku Ikenogami, Kazunori Kurihara, Toshio Taniguchi, Mitsuru Takahashi, Akio Iida
  • Patent number: 7803801
    Abstract: The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(?O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: September 28, 2010
    Assignee: Japan Tobacco, Inc.
    Inventors: Yoshitoshi Kodama, Satoru Noji, Katsuaki Imamura, Ryo Mizojiri, Kenta Aoki, Hideo Takagi, Yuichi Naka, Goro Ito, Kiyotaka Shinoda, Akihito Fujiwara, Kazunori Kurihara, Masaru Tanaka
  • Publication number: 20060205731
    Abstract: The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(?O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
    Type: Application
    Filed: February 28, 2006
    Publication date: September 14, 2006
    Applicant: JAPAN TOBACCO INC.
    Inventors: Yoshitoshi Kodama, Satoru Noji, Katsuaki Imamura, Ryo Mizojiri, Kenta Aoki, Hideo Takagi, Yuichi Naka, Goro Ito, Kiyotaka Shinoda, Akihito Fujiwara, Kazunori Kurihara, Masaru Tanaka
  • Publication number: 20060089392
    Abstract: The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.
    Type: Application
    Filed: October 17, 2005
    Publication date: April 27, 2006
    Inventors: Atsushi Hagiwara, Taku Ikenogami, Kazunori Kurihara, Toshio Taniguchi, Mitsuru Takahashi, Akio Ida
  • Patent number: D935372
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: November 9, 2021
    Assignee: Subaru Corporation
    Inventor: Kazunori Kurihara